CASI Pharmaceuticals (NASDAQ:CASI), Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative therapies in oncology and immunology. Headquartered in Princeton, New Jersey, with research and development operations in Shanghai, China, the company leverages its dual‐centered infrastructure to accelerate the translation of novel small molecules from discovery through late‐stage clinical trials. CASI’s core mission is to address unmet medical needs in cancer and immune disorders by advancing differentiated compounds and combination regimens.
The company’s pipeline features several targeted therapies and immunomodulators. Lead asset belinostat, a histone deacetylase inhibitor, is approved in the U.S. for peripheral T‐cell lymphoma and is under evaluation in combination studies. CASI is also developing plinabulin, a microtubule‐destabilizing agent designed to mitigate chemotherapy‐induced neutropenia, and avadomide, an oral cereblon‐binding molecule for various hematologic malignancies. Additional programs include selective retinoic acid receptor agonists and toll‐like receptor agonists, positioning CASI at the forefront of novel mechanism research.
Founded in 2013 as a spin‐out from the China oncology research unit of a global pharmaceutical leader, CASI went public on the NASDAQ exchange in 2015 under the ticker symbol “CASI.” Since inception, the company has established partnerships with leading academic institutions and multinational biopharma organizations to expand its clinical development capabilities. With dual regulatory filings planned in North America and Greater China, CASI aims to bring its first proprietary therapies to patients worldwide.
Under the guidance of its executive leadership and board of directors—comprised of seasoned drug‐development and commercialization experts—CASI Pharmaceuticals continues to advance its pipeline through carefully designed trials and strategic collaborations. By combining scientific innovation with global regulatory and market expertise, the company endeavors to deliver new treatment options for patients facing challenging cancers and immune disorders.
